In a report released today, Cory Kasimov from J.P. Morgan maintained a Buy rating on Bluebird Bio (BLUE), with a price target of $195. The company’s shares closed yesterday at $117.46.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.2% and a 41.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $162.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $197.25 and a one-year low of $87.49. Currently, Bluebird Bio has an average volume of 463.4K.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is neutral on the stock. Last month, Jason Cole, the Chief Operating and of BLUE bought 562 shares for a total of $28,387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
